^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

Tecartus (brexucabtagene autoleucel)

i
Other names: KTE-X19, autologous anti-CD19 chimeric antigen receptor T cells, Brexu-cel, FKC889
Company:
Fosun Kite, Gilead
Drug class:
CD19-targeted CAR-T immunotherapy
Related drugs:
16d
NGS MRD Negativity on Day 28 after Brexu Cel in Adults with R/R ALL Is Associated with Favorable Progression Free Survival (ASH 2024)
Introduction: Brexucabtagene autoleucel (brexu cel) is a CD19-targeted chimeric antigen receptor (CAR) T cell therapy approved for the treatment of adults with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL)...No differences were observed with respect to sex, TP53 mutation status, prior inotuzumab (ino) or blinatumomab (blina) exposure, disease burden prior to CAR, or development of any cytokine release syndrome (CRS) or any neurotoxicity with brexu cel... In a large real-world cohort of adults with R/R B-ALL infused with brexu cel, we identified practice variation regarding the use of consolidative HCT. Among brexu cel recipients who entered an MRD- CR, we identified ClonoSeq NGS MRD negativity as a novel predictive factor of favorable oncologic outcomes, even without a consolidative HCT. Similar results have been obtained in pediatric ALL patietns ftreated with 41BB-based tisagenleucleucel (Pulsipher et al., Blood Cancer Discovery 2022).
Clinical • Next-generation sequencing • IO biomarker • Minimal residual disease
|
TP53 (Tumor protein P53)
|
TP53 mutation
|
clonoSEQ
|
Blincyto (blinatumomab) • Besponsa (inotuzumab ozogamicin) • Tecartus (brexucabtagene autoleucel)
23d
Therapy-Related Acute Myeloid Leukemia after CAR-T Cell Therapy with Brexucabtagene Autoleucel for Mantle Cell Lymphoma. (PubMed, Case Rep Oncol)
Secondary malignancies seem more frequent after CAR-T therapies. More studies are needed to assess potential long-term toxicities of CAR-T cell therapies including the frequency of secondary myeloid malignancies.
Journal • CAR T-Cell Therapy
|
TP53 (Tumor protein P53)
|
Tecartus (brexucabtagene autoleucel)
25d
Trial primary completion date
|
CD20 negative
|
cyclophosphamide • fludarabine IV • Tecartus (brexucabtagene autoleucel)
3ms
Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCL (clinicaltrials.gov)
P2, N=60, Recruiting, H. Lee Moffitt Cancer Center and Research Institute | Not yet recruiting --> Recruiting
Enrollment open
|
Jaypirca (pirtobrutinib) • Tecartus (brexucabtagene autoleucel)
3ms
Trial primary completion date
|
cyclophosphamide • fludarabine IV • Tecartus (brexucabtagene autoleucel)
3ms
Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCL (clinicaltrials.gov)
P2, N=60, Not yet recruiting, H. Lee Moffitt Cancer Center and Research Institute
New P2 trial
|
Jaypirca (pirtobrutinib) • Tecartus (brexucabtagene autoleucel)
3ms
(Cohort 3) ZUMA-2: Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 3) (clinicaltrials.gov)
P2, N=90, Active, not recruiting, Kite, A Gilead Company | Trial completion date: Oct 2038 --> Jun 2025 | Trial primary completion date: Nov 2023 --> Nov 2024
Trial completion date • Trial primary completion date
|
cyclophosphamide • fludarabine IV • Tecartus (brexucabtagene autoleucel)
4ms
ZUMA-25: Study of Brexucabtagene Autoleucel in Adults With Rare B-cell Malignancies (clinicaltrials.gov)
P2, N=19, Active, not recruiting, Kite, A Gilead Company | Recruiting --> Active, not recruiting | N=90 --> 19
Enrollment closed • Enrollment change • Pan tumor
|
cyclophosphamide • fludarabine IV • Tecartus (brexucabtagene autoleucel)
4ms
Enrollment open
|
CCND1 (Cyclin D1)
|
Tecartus (brexucabtagene autoleucel)
4ms
Enrollment open
|
CD19 (CD19 Molecule)
|
Tecartus (brexucabtagene autoleucel)
4ms
Enrollment open
|
Blincyto (blinatumomab) • Besponsa (inotuzumab ozogamicin) • Tecartus (brexucabtagene autoleucel)
5ms
New P2 trial • CAR T-Cell Therapy
|
Imbruvica (ibrutinib) • Rituxan (rituximab) • cyclophosphamide • Tecartus (brexucabtagene autoleucel)
6ms
ZUMA-4: Study Evaluating Brexucabtagene Autoleucel (KTE-X19) in Pediatric and Adolescent Participants With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
P1/2, N=95, Active, not recruiting, Kite, A Gilead Company | Recruiting --> Active, not recruiting | Trial completion date: Aug 2027 --> Mar 2026 | Trial primary completion date: Dec 2025 --> Sep 2024
Enrollment closed • Trial completion date • Trial primary completion date
|
cyclophosphamide • fludarabine IV • Tecartus (brexucabtagene autoleucel)
6ms
BREXUCABTAGENE AUTOLEUCEL (BREXU-CEL) AS CONSOLIDATION TREATMENT IN ADULTS WITH B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA WITH MARROW BLASTS <5%, INCLUDING PATIENTS (PTS) WITH NGS MRD NEGATIVE DISEASE (EHA 2024)
Prior therapy included blinatumomab (94%), inotuzumab (88%), allo-SCT (24%)...Tocilizumab was needed in 15 pts (44%), dexamethasone 7 pts (21%), and 2 pts needed ICU care... Use of brexu-cel in pts with low tumor burden is associated with low rates of G3-4 CRS/ICANS. We noted CART expansion in pts with no morphologic disease prior to LD. Prospective trials are planned to assess role of CART in low tumor burden setting, including MRD+ and as consolidation strategy.
Clinical • Next-generation sequencing • Minimal residual disease
|
CRLF2 (Cytokine Receptor Like Factor 2)
|
clonoSEQ
|
Blincyto (blinatumomab) • Besponsa (inotuzumab ozogamicin) • Tecartus (brexucabtagene autoleucel) • Actemra IV (tocilizumab)
7ms
Enrollment open
|
Gazyva (obinutuzumab) • Yescarta (axicabtagene ciloleucel) • Tecartus (brexucabtagene autoleucel) • Columvi (glofitamab-gxbm)
7ms
Early CAR- CD4+ T-lymphocytes recovery following CAR-T cell infusion: A worse outcome in diffuse large B cell lymphoma. (PubMed, EJHaem)
Among possible determinants of CD4+ T cell recovery, we recognized infusion of a 4-1BB product (tisagenlecleucel, TSA) in comparison with a CD28 (axicabtagene/brexucabtagene, AXI/BRX) (hazard ratio [HR] [95% CI]: 5.79 [1.16-24.12] p = 0.016). We conclude that a faster CAR- CD4+ T cell recovery is associated with TSA as compared to AXI/BRX. Month-1 CAR- CD4+ T cell subset recovery could represent a "red flag" for CAR-T cell therapy failure in DLBCL patients.
Journal • CAR T-Cell Therapy
|
CD4 (CD4 Molecule)
|
Yescarta (axicabtagene ciloleucel) • Kymriah (tisagenlecleucel-T) • Tecartus (brexucabtagene autoleucel)
7ms
ZUMA-25: Study of Brexucabtagene Autoleucel in Adults With Rare B-cell Malignancies (clinicaltrials.gov)
P2, N=90, Recruiting, Kite, A Gilead Company | Trial completion date: Dec 2027 --> Mar 2025 | Trial primary completion date: Dec 2027 --> Mar 2025
Trial completion date • Trial primary completion date • Pan tumor
|
cyclophosphamide • fludarabine IV • Tecartus (brexucabtagene autoleucel)
7ms
Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells (clinicaltrials.gov)
P2, N=700, Enrolling by invitation, Kite, A Gilead Company | Trial completion date: Mar 2041 --> Dec 2040 | Trial primary completion date: Mar 2041 --> Dec 2040
Trial completion date • Trial primary completion date
|
Yescarta (axicabtagene ciloleucel) • Tecartus (brexucabtagene autoleucel) • KITE-222 • KITE-363 • KITE-439 • KITE-585 • KITE-718
8ms
Matching-Adjusted Indirect Comparison of Brexucabtagene Autoleucel (ZUMA-2) and Pirtobrutinib (BRUIN) in Patients with Relapsed/Refractory Mantle Cell Lymphoma Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor. (PubMed, Adv Ther)
Findings suggest that brexu-cel may offer clinically and statistically significant benefits regarding objective response, complete response, and progression-free survival compared to pirtobrutinib among patients with R/R MCL after prior cBTKi therapy. Given the short follow-up and high degree of censoring in BRUIN, an analysis incorporating updated BRUIN data may provide more definitive overall survival results.
Journal
|
TP53 (Tumor protein P53)
|
TP53 mutation
|
Jaypirca (pirtobrutinib) • Tecartus (brexucabtagene autoleucel)
8ms
MT2017-45: CAR-T Cell Therapy for Heme Malignancies (clinicaltrials.gov)
P=N/A, N=144, Active, not recruiting, Masonic Cancer Center, University of Minnesota | Recruiting --> Active, not recruiting | N=240 --> 144 | Trial primary completion date: Jun 2028 --> Feb 2024
Enrollment closed • Enrollment change • Trial primary completion date • CAR T-Cell Therapy
|
CD19 (CD19 Molecule)
|
CD19 expression
|
cyclophosphamide • Yescarta (axicabtagene ciloleucel) • Breyanzi (lisocabtagene maraleucel) • Kymriah (tisagenlecleucel-T) • fludarabine IV • Tecartus (brexucabtagene autoleucel) • Abecma (idecabtagene vicleucel)
9ms
Liquid biopsy approach to monitor the efficacy and response to CAR-T cell therapy. (PubMed, J Immunother Cancer)
With the simultaneous detection of the CAR-T cells and the B cell malignancy in patient peripheral blood, the HDSCA-HemeCAR workflow may be considered for risk monitoring and patient management.
Journal • CAR T-Cell Therapy • Liquid biopsy • IO biomarker • Biopsy
|
CD20 (Membrane Spanning 4-Domains A1) • CD22 (CD22 Molecule)
|
CD19 expression
|
Yescarta (axicabtagene ciloleucel) • Tecartus (brexucabtagene autoleucel)
9ms
Study of Brexucabtagene Autoleucel Plus Dasatinib in Adults With Acute Lymphoblastic Leukemia (clinicaltrials.gov)
P1, N=20, Recruiting, Stanford University | Phase classification: P1b --> P1
Phase classification
|
CD19 (CD19 Molecule)
|
CD19 expression
|
dasatinib • Tecartus (brexucabtagene autoleucel)
9ms
New P2 trial
|
cyclophosphamide • fludarabine IV • Tecartus (brexucabtagene autoleucel)
10ms
The HSP90-MYC-CDK9 network drives therapeutic resistance in mantle cell lymphoma. (PubMed, Exp Hematol Oncol)
Brexucabtagene autoleucel CAR-T therapy is highly efficacious in overcoming resistance to Bruton's tyrosine kinase inhibitors (BTKi) in mantle cell lymphoma...Pharmaceutical co-targeting of HSP90 and CDK9 synergistically diminished MYC activity, leading to potent anti-MCL activity. Collectively, our study revealed that HSP90-MYC-CDK9 network is the primary driving force of therapeutic resistance.
Journal • IO biomarker
|
CDK9 (Cyclin Dependent Kinase 9) • HSP90AA1 (Heat Shock Protein 90 Alpha Family Class A Member 1Heat Shock Protein 90 Alpha Family Class A Member 1) • HSP90AB1 (Heat Shock Protein 90 Alpha Family Class B Member 1)
|
MYC expression
|
Tecartus (brexucabtagene autoleucel)
10ms
New P2 trial
|
Gazyva (obinutuzumab) • Yescarta (axicabtagene ciloleucel) • Tecartus (brexucabtagene autoleucel) • Columvi (glofitamab-gxbm)
11ms
Trial completion date • Trial primary completion date
|
CD20 negative
|
cyclophosphamide • fludarabine IV • Tecartus (brexucabtagene autoleucel)
11ms
Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL) (clinicaltrials.gov)
P2, N=60, Recruiting, H. Lee Moffitt Cancer Center and Research Institute | Trial primary completion date: Nov 2026 --> Nov 2028
Trial primary completion date • Minimal residual disease
|
Tecartus (brexucabtagene autoleucel)
11ms
(Cohort 3) ZUMA-2: Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 3) (clinicaltrials.gov)
P2, N=90, Active, not recruiting, Kite, A Gilead Company | Trial primary completion date: Jul 2024 --> Nov 2023
Trial primary completion date
|
cyclophosphamide • fludarabine IV • Tecartus (brexucabtagene autoleucel)
12ms
New P2 trial
|
CD19 (CD19 Molecule)
|
CD19 positive • CD19 expression
|
Tecartus (brexucabtagene autoleucel)
12ms
Cladribine and Cyclophosphamide Lymphodepletion Prior to Brexucabtagene Autoleucel in Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia and Mantle Cell Lymphoma (ASH 2023)
Introduction: Fludarabine and cyclophosphamide (Flu/Cy) lymphodepletion (LD) prior to chimeric antigen T-cell (CAR T) infusion favorably impacts CAR T expansion and efficacy...Three deaths (2 Cla/Cy) occurred before day 100, all due to refractory fungemia post anakinra... Cla/Cy LD prior to brexu-cel is feasible in ALL and MCL patients with comparable efficacy. Toxicity rates including CRS, ICANS and early infections were similar to those seen with Flu/Cy, but there was a trend towards earlier recovery of neutrophils, B-, and T-cells with Cla/Cy. The trend was demonstrable even in patients at high risk of prolonged post-CAR T neutropenia as identified by the HS.
CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
|
clonoSEQ
|
cyclophosphamide • cladribine • fludarabine IV • Tecartus (brexucabtagene autoleucel) • Kineret (anakinra)
12ms
Real World Outcomes in Patients with Ph-like ALL at the University of New Mexico (ASH 2023)
While many therapies are under investigation including the addition of a tyrosine kinase inhibitor or ruxolitinib to conventional chemotherapy, a standardized and molecularly-based approach to treating patients with Ph-like ALL is not yet defined. There also remain questions about the efficacy of integrating inotuzumab ozogamicin or blinatumomab into first-line therapy for these patients...1 patient received Car T cell therapy with Brexucabtagene autoleucel following relapse after allogeneic stem cell transplant... We identified 9 patients who met inclusion criteria. All 9 patients self-identified as either ‘American Indian or Alaska Native’ or ‘Hispanic or Latino. ‘ The median age at diagnosis was 34 and the mean BMI at diagnosis was 34.
Clinical • Real-world evidence • IO biomarker • Real-world
|
ABL1 (ABL proto-oncogene 1) • BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • PDGFRB (Platelet Derived Growth Factor Receptor Beta) • CRLF2 (Cytokine Receptor Like Factor 2) • IKZF1 (IKAROS Family Zinc Finger 1) • P2RY8 (P2Y Receptor Family Member 8)
|
CD20 positive • IKZF1 mutation
|
Jakafi (ruxolitinib) • Blincyto (blinatumomab) • Besponsa (inotuzumab ozogamicin) • Tecartus (brexucabtagene autoleucel)
almost1year
New P2 trial • Minimal residual disease
|
Tecartus (brexucabtagene autoleucel)
1year
A Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel (KTE-X19) in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ZUMA-3) (clinicaltrials.gov)
P1/2, N=125, Completed, Kite, A Gilead Company | Active, not recruiting --> Completed | Trial completion date: Nov 2034 --> Nov 2023
Trial completion • Trial completion date
|
CD19 (CD19 Molecule)
|
CD19 expression
|
cyclophosphamide • fludarabine IV • Tecartus (brexucabtagene autoleucel)
1year
CAR-T THERAPIES AS A NEW APPROCH IN THE TREATMENT OF ELDERLY PATIENTS WITH NHL (SIOG 2023)
The main goals of the symposium are: to share the benefits of Yescarta in 3/2L of LBDCL in the elderly patient setting share the benefits of Tecartus in MCL, a disease with major incidence in older patients. Target audience: Hematologists, geriatricians, nurses and other healthcare professionals in contact with geriatric cancer patients.
Clinical
|
Yescarta (axicabtagene ciloleucel) • Tecartus (brexucabtagene autoleucel)
1year
Matching-Adjusted Indirect Comparison (MAIC) of Brexucabtagene Autoleucel (Brexu-cel) and Pirtobrutinib in Patients with Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor (cBTKi) (ASH 2023)
While acknowledging the inherent limitations of an unanchored indirect comparison, our findings suggest that brexu-cel offers clinically and statistically significant efficacy benefits in terms of ORR, CR, and PFS compared to pirtobrutinib in patients with R/R MCL after prior cBTKi therapy. Both treatments were not statistically different in terms of OS and DOR although the estimated hazard ratios indicated a favorable trend for brexu-cel; however, given the relatively shorter follow-up and the high degree of censoring in BRUIN, an updated analysis incorporating longer follow-up data with more events from BRUIN could provide more reliable results. Although efforts were made to ensure a robust approach to the selection of prognostic factors for inclusion in the model, the possibility of some residual confounding variables cannot be completely ruled out.
Clinical
|
TP53 (Tumor protein P53)
|
TP53 mutation
|
Jaypirca (pirtobrutinib) • Tecartus (brexucabtagene autoleucel)
1year
Real-World Incidence, Characteristics and Management of Cytokine Release Syndrome Induced By Chimeric Antigen Receptor T-Cell Therapy across Hematologic Malignancies (ASH 2023)
Background: Cytokine release syndrome (CRS) is a potentially life-threatening, supraphysiologic response following immunotherapy resulting in the activation or engagement of endogenous or infused T cells and/or other immune effector cells. Table 1 summarizes data by indication. Incidence of CRS ranged from 56% (104/185) in DLBCL to 72% (66/92) in MCL. Excluding categories with small numbers of cases (<15), CRS incidence also varied by individual CAR-T therapy and underlying indication and ranged from 35% for idecabtagene vicleucel in MM to 73% for brexucabtagene autoleucel in MCL.
Clinical • CAR T-Cell Therapy • Real-world evidence • Real-world
|
Tecartus (brexucabtagene autoleucel) • Actemra IV (tocilizumab) • Abecma (idecabtagene vicleucel)
1year
Real World Results of Brexucabtagene Autoleucel for Patients with Relapsed/Refractory Mantle Cell Lymphoma - First German/Swiss Analysis (ASH 2023)
Preceding CAR-T, median number of treatments was 3 (range 1-9), all patients had prior Rituximab and Ibrutinib, 62 patients (56%) had received autologous stem cell transplantation (SCT) and 11 patients had received an allogeneic SCT. 111 patients have been identified: median age at diagnosis was 64.3 years (range 42.3-79.5; 19/99 patients ≥ 70), 18% female (not known (nk) 2.7%); ethnicity 66.7% Caucasian (nk 30.6%). Disease characteristics: 80/88 had stage 3/4 (91%), histology was classical in 34/57 cases (60%) and blastoid in 19/57 (33%), respectively. MIPI score was low 14/53 (26%), intermediate 17 (32%), high 21 (40%).
Clinical • Real-world evidence • IO biomarker • Real-world
|
TP53 (Tumor protein P53)
|
Imbruvica (ibrutinib) • Rituxan (rituximab) • Tecartus (brexucabtagene autoleucel)
1year
Real-World Outcomes of Brexucabtagene Autoleucel (brexu-cel) for Relapsed or Refractory (R/R) Adult B-Cell Acute Lymphoblastic Leukemia (B-cell ALL): Evidence from the CIBMTR Registry (ASH 2023)
Pts received a median of 4 prior lines of therapy (range 1-13); 46% had prior inotuzumab and 58% had prior blinatumomab...Treatment for CRS and/or ICANS consisted mainly of tocilizumab (67%) and corticosteroids (51%)...Updated data with longer follow-up will be reported at the time of presentation. *First and second authors are equal contributors
Clinical • Real-world evidence • Real-world
|
Blincyto (blinatumomab) • Besponsa (inotuzumab ozogamicin) • Tecartus (brexucabtagene autoleucel) • Actemra IV (tocilizumab)
1year
Post CAR-T Peripheral Lymphocytosis and Its Kinetics Are a Potential Biomarker for Response and Immune Mediated Toxicities (ASH 2023)
ALC data for 84 pts who received CD19 CAR-T (77 pts with axicabtagene ciloleucel and 7 pts with brexucabtagene autoleucel) for non-Hodgkin lymphoma (NHL) were included as a comparison...Furthermore, ALC dynamics differed by BCMA CAR-T product, with cilta-cel exhibiting later CRS with higher max-ALC peaking at a later day when compared to ide-cel. Furthermore, higher max-ALC and absolute ALC increase were associated with deeper response (VGPR/CR) and sustainable response on follow up. Our findings suggest that peripheral lymphocytosis after CAR-T is disease specific (NHL vs MM) and post CAR-T lymphocytosis in peripheral blood is a potential biomarker for clinical outcomes and toxicity.
IO biomarker
|
CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
|
Yescarta (axicabtagene ciloleucel) • Tecartus (brexucabtagene autoleucel) • Abecma (idecabtagene vicleucel) • Carvykti (ciltacabtagene autoleucel)
1year
Simvastatin with Intrathecal Dexamethasone Reduces Neurotoxicity in Adults Receiving Chimeric Antigen Receptor (CAR) T-Cells Treatment (ASH 2023)
Similarly, with brexucabtagene autoleucel (brexu-cel), ICANS also occurred in approximately 60% with ≥ G3 occurring in 26-31% of patients...Tocilizumab (8 mg/kg) was administered to 11 patients (73.3%) with the median number of doses being 1 (range 1 to 4)...One patient with Richter's had progressive disease at day 30, 4 patients had partial remission, and 10 patients had a complete remission for an ORR of 93%. Conclusions Preliminary results show that simvastatin and intrathecal dexamethasone appear to be feasible, safe, and effective in reducing the incidence and severity of ICANS in patients receiving axi-cel and brexu-cel.
Clinical • IO biomarker
|
CRP (C-reactive protein)
|
Yescarta (axicabtagene ciloleucel) • Tecartus (brexucabtagene autoleucel) • Actemra IV (tocilizumab)
1year
Post-CAR-T Minimal Residual Disease (MRD) Monitoring in Mantle Cell Lymphoma Enables Early Relapse Detection (ASH 2023)
INTRODUCTION: Over 40% of patients with mantle cell lymphoma (MCL) will progress within 1 year after treatment with brexucabtagene autoleucel (Brexu-cel)(Michael Wang et al... Evidence from the ZUMA-2 study and our study highlights the significance of early post-CAR-T MRD as an independent prognostic marker for predicting disease recurrence and durable remissions in MCL. Combining MRD measurements with PET-CT at months 1, 3, and 6 after CAR-T therapy can effectively identify high-risk patients for disease progression, offering promising potential to improve outcomes in MCL.
IO biomarker • Minimal residual disease
|
TP53 (Tumor protein P53)
|
TP53 mutation
|
clonoSEQ
|
Tecartus (brexucabtagene autoleucel)